Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Warner-Lambert

This article was originally published in The Tan Sheet

Executive Summary

FTC approves planned merger but requires divestiture of an overlapping consumer product marketed only in the U.S., Pfizer announces May 25. While neither company would say which product must be divested, Pfizer calls the requirement "baffling." The merged firm most likely will have to "rid" itself of either the Rid or Nix pediculicides, which had a combined 58.1% dollar share in the lice category for the 52 weeks ended Dec. 26, according to data from Chicago-based Information Resources, Inc. Both companies also market mouthwashes, W-L with Listerine and Pfizer with Plax. The closing is targeted for early to mid-June, Pfizer says

You may also be interested in...



Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

Bayer Rid Pediculicide Marketing Begins With Mousse Launch

Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel